A new purpose for an old drug: Inhibiting autophagy with clarithromycin

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1255-1256

  Altman, Jessica K ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; CLARITHROMYCIN; DASATINIB; IMATINIB; NILOTINIB; PONATINIB;

AUTOPHAGY; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE;

EID: 84862749336     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.661857     Document Type: Note

References (13)

1. Hippert MM, O'Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006;66:9349-9351.
2. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109-1123.
3. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005;120:237-248. (Pubitemid 40174766)
4. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117:326-336. (Pubitemid 46203961)
5. Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011:121-127.
6. Diamond JM, Melo JV. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011;52(Suppl. 1):12-22.
7. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011;95:761-791, viii.
8. Nakamura M, Kikukawa Y, Takeya M, et al. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010;37:815-820.
9. Gay F, Rajkumar V, Coleman M, et al. Clarithromycin (Biaxin)- lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010;85:664-669.
10. Spahn JD, Fost DA, Covar R, et al. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 2001;87:501-505. (Pubitemid 34001039)
11. Biaxin based antibiotic therapy in previously untreated, advanced stage indolent lymphoma. [Accessed 1/6/12]. Available from: http://clinicaltrials.gov/
12. Lenalidomide, dexamethasone and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma. [Accessed 1/6/12]. Available from: http://clinicaltrials.gov/
13. Carella AM, Beltrami G, Pica G, et al. Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma 2012;53:1409-1411.